| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Health Care
| AbbVie is focused on enhancing its product offerings through robust drug development and trial phases, particularly in oncology and immunology, as a response to market dynamics. The company is demonstrating a solid pipeline with promising results from late-stage trials, indicating a strong commitment to innovation in healthcare. Additionally, the expansion into skincare products showcases AbbVie's diversified approach to meeting consumer needs. However, the ongoing decline of Humira necessitates continuous strategic shifts to maintain market position. |
| The price action of ABBVIE INC (ABBV) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -0.1 is modestly bearish. The market sentiment at 1.3 is very bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for ABBV since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 1.3, and the negative at -0 on 2026-09-04. The forces of and Stock Price Trend (-0.1) will drive down the price. The forces of Sector Price Trend (0), Price Level Sentiment (0), Market Risk Appetite (1), Option Sentiment (1.5), Valuation Sentiment (2.6), and Sentiment towards Fundamentals (2.7) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| ABBV | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-04 | 0%(0%) | 256.37 | 2.34% | 45 | 56 | 49 | -1.51% | -0.34% | -0.1 | 0 | 0.7% | 1.3 | Long | 55% | 2.7 | 2 |
| 2026-09-03 | 0%(0%) | 260.3 | 2.5% | 63 | 62 | 54 | -0.54% | -0.04% | 0.4 | 0 | 0.4% | 1.3 | Long | 55% | 2.8 | -1 |
| 2026-09-02 | 0%(0%) | 261.71 | 2.7% | 70 | 63 | 57 | 0.67% | -0.19% | 0 | 0.4 | 0.7% | 1 | Long | 55% | 2.2 | -1 |
| 2026-09-01 | 0%(0%) | 259.96 | 2.79% | 66 | 63 | 64 | 1.4% | 0.04% | 0 | 0.2 | 0.9% | 0.8 | Long | 55% | 1.4 | -1 |
| 2026-08-31 | 0%(0%) | 256.38 | 2.96% | 56 | 58 | 49 | 0.36% | 0.23% | 0.1 | 0 | 0.5% | 0.8 | Long | 55% | 0.9 | -1 |
| 2026-08-30 | 0%(0%) | -0 | 0 | 0.9 | 1.3 | -1 | ||||||||||
| 2026-08-29 | 0%(0%) | -0 | 0 | 0.9 | 0.4 | -1 | ||||||||||
| 2026-08-28 | 0%(0%) | 255.47 | 3.08% | 55 | 59 | 29 | -0.99% | 0.23% | -0 | -0.3 | 0.8% | 1.1 | Short | 55% | 0.4 | -1 |
| 2026-08-27 | 0%(0%) | 258.02 | 3.05% | 63 | 64 | 32 | -1.82% | 0.27% | 0.2 | -0.4 | 1.1% | 1.6 | Short | 55% | 1.6 | -1 |
| 2026-08-26 | 0%(0%) | 262.81 | 2.99% | 79 | 74 | 38 | -1.1% | 0.58% | 0.5 | -0 | 0.8% | 1.3 | Long | 55% | 0.9 | -1 |
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● AbbVie Inc. (ABBV) – Equity Research Report Sun. Mar 1, 2026 | ||
| 2026-09-04 17:01:29 AbbVie is navigating a competitive landscape against major players like Pfizer, focusing on innovation to sustain its market leadership. |
| 2026-09-04 17:01:29 Analyst opinions suggest that AbbVie's stock remains a 'Buy,' supported by solid fundamentals and positive growth projections following recent acquisitions. |
| 2026-09-04 17:01:29 Institutional investors are actively purchasing shares of AbbVie, indicating confidence in the company's long-term strategy and market position. |
| 2026-09-04 17:01:29 The revenue decline of AbbVie's flagship drug, Humira, raises concerns about the company's future earnings and its ability to maintain dividends. |
| 2026-09-04 17:01:29 AbbVie is successfully advancing its pipeline, particularly in cancer treatments like Etentamig, showcasing strong response rates in clinical trials. |
| 2026-09-04 15:46:32 The potential impacts of upcoming patent expirations on Pfizer's valuation and market performance. |
| 2026-09-04 15:46:32 The comparison of the competitive positions of AbbVie and Pfizer in the healthcare market, considering their product pipelines and market strategies. |
| 2026-09-04 15:46:32 AbbVie's strategic shift towards immunology to counterbalance the decline of its key product, Humira. |
| 2026-09-04 15:46:32 The competitive analysis of AbbVie and Pfizer regarding their market valuations, highlighting the disparity in their stock prices and future prospects. |